KLK7: A Potential Drug Target and Biomarker (G5650)

Target Name: KLK7

NCBI ID: G5650

KLK7: A Potential Drug Target and Biomarker

Kallikrein-related peptidase 7 (KLK7) is a serine proteases that belong to the group of serine proteases known as kallikreins. Kallikreins are a family of transmembrane proteins that contain a catalytic active site on one side and a variable region on the other side. The variable region of kallikreins includes a unique domain that is involved in the recognition of extracellular matrix (ECM) components.

KLK7 is a 14 kDa protein that is expressed in a variety of tissues, including heart, liver, and kidney. It is involved in the degradation of ECM components, including extracellular matrix proteins such as collagen and elastin. This protein has also been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway.

KLK7 has also been shown to be involved in the regulation of inflammation. Studies have shown that KLK7 can induce the production of pro-inflammatory cytokines, such as TNF-伪, IL-1尾, and IL-6, in human monocytes and macrophages. This protein has also been shown to interact with several different signaling pathways, including the NF-kappa-B pathway and the PI3K/AKT pathway.

Despite its involvement in several different biological processes, KLK7 has not yet been identified as a drug target or biomarker. However, the potential implications of its involvement in these processes make it an attractive target for future research.

One potential mechanism by which KLK7 could be targeted as a drug is by inhibiting its activity as a proteases. KLK7 is a potent proteases that is involved in the degradation of ECM components, including collagen and elastin. By inhibiting its activity, researchers may be able to slow down or even reverse the degradation of these components, potentially leading to changes in cellular behavior.

Another potential mechanism by which KLK7 could be targeted as a drug is by modulating its activity through the regulation of its expression. KLK7 has been shown to be involved in several different signaling pathways, including the TGF-β pathway and the NF-kappa-B pathway. By modulating its expression, researchers may be able to alter its activity and potentially target its involvement in these processes.

In addition to its potential as a drug target, KLK7 also has potential as a biomarker. The degradation of ECM components by KLK7 is a well-established hallmark of several diseases, including cancer, fibrosis, and neurodegenerative diseases. By detecting the degradation of these components in tissues or fluids, researchers may be able to use KLK7 as a biomarker for these diseases.

Overall, the potential of KLK7 as a drug target or biomarker makes it an attractive target for future research. While more research is needed to fully understand its mechanisms of action and potential therapeutic applications, its involvement in several different biological processes makes it a promising molecule for further study.

Protein Name: Kallikrein Related Peptidase 7

Functions: May catalyze the degradation of intercellular cohesive structures in the cornified layer of the skin in the continuous shedding of cells from the skin surface. Specific for amino acid residues with aromatic side chains in the P1 position. Cleaves insulin A chain at '14-Tyr-|-Gln-15' and insulin B chain at '6-Leu-|-Cys-7', '16-Tyr-|-Leu-17', '25-Phe-|-Tyr-26' and '26-Tyr-|-Thr-27'. Could play a role in the activation of precursors to inflammatory cytokines

More Common Targets